Vor Biopharma Stock (NASDAQ:VOR)
Previous Close
$1.05
52W Range
$0.70 - $3.14
50D Avg
$0.92
200D Avg
$1.68
Market Cap
$71.82M
Avg Vol (3M)
$857.10K
Beta
-0.34
Div Yield
-
VOR Company Profile
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
VOR Performance
Peer Comparison
| Ticker | Company |
|---|---|
| GRCL | Gracell Biotechnologies Inc. |
| NUVL | Nuvalent, Inc. |
| NRIX | Nurix Therapeutics, Inc. |
| KYMR | Kymera Therapeutics, Inc. |
| TALS | Tourmaline Bio, Inc. |
| CGEM | Cullinan Oncology, Inc. |
| KNSA | Kiniksa Pharmaceuticals, Ltd. |
| FHTX | Foghorn Therapeutics Inc. |
| DAWN | Day One Biopharmaceuticals, Inc. |
| EWTX | Edgewise Therapeutics, Inc. |
| VTYX | Ventyx Biosciences, Inc. |
| ERAS | Erasca, Inc. |
| BOLT | Bolt Biotherapeutics, Inc. |
| GLUE | Monte Rosa Therapeutics, Inc. |
| ACLX | Arcellx, Inc. |
| DSGN | Design Therapeutics, Inc. |
| AUTL | Autolus Therapeutics plc |
| ACET | Adicet Bio, Inc. |
| LYRA | Lyra Therapeutics, Inc. |
| STTK | Shattuck Labs, Inc. |